Endothelial Cell News 4.33 September 30, 2019 | |
| |
TOP STORYAngiopoietin-Like 4 Binds Neuropilins and Cooperates with VEGF to Induce Diabetic Macular Edema Angiopoietin-like 4 bound directly to neuropilin 1 (NRP1) and NRP2 on endothelial cells (ECs), leading to rapid activation of the RhoA/ROCK signaling pathway and breakdown of EC-EC junctions. [J Clin Invest] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Generation of Blood Vessel Organoids from Human Pluripotent Stem Cells The authors describe a protocol to generate self-organizing 3D human blood vessel organoids from human pluripotent stem cells that exhibited morphological, functional and molecular features of human microvasculature. [Nat Protoc] Abstract Abl Family Tyrosine Kinases Govern IgG Extravasation in the Skin in a Murine Pemphigus Model Researchers showed in a murine model of pemphigus, a prototypic cutaneous autoantibody-mediated disorder, that blood-circulating IgG extravasated into the skin in a time- and dose-dependent manner under homeostatic conditions. This IgG extravasation was unaffected by depletion of Fcγ receptors, but was largely attenuated by specific ablation of dynamin-dependent endocytic vesicle formation in blood endothelial cells. [Nat Commun] Full Article Scientists investigated whether uric acid induced endothelial-to-mesenchymal transition in HUVECs and an animal model of hyperuricemia fed with 2% oxonic acid for four weeks. [FASEB J] Abstract Investigators showed that HUVECs were more sensitive to the cytotoxic activity of benzo[a]pyrene diol epoxide (BPDE) than human smooth muscle cells and human pericytes. HUVECs displayed a detraction in the repair of BPDE-induced adducts, as determined through the comet assay and the quantification of BPDE adducts in post-labelling experiments. [Sci Rep] Full Article Researchers reproduced a directed differentiation of brain microvascular endothelial cells from two fluorescently labeled human induced pluripotent stem cell lines and demonstrated physiological permeability of Lucifer yellow over six days. [Sci Rep] Full Article Inhibiting Expression of CXCl9 Promotes Angiogenesis in MSCs-HUVECs Co-Culture Scientists investigated the effect of rat bone-marrow derived mesenchymal stem cells (MSCs) on angiogenic capability of HUVECs in growth medium and osteogenic induction medium. [Arch Biochem Biophys] Abstract BK-induced bradykinin-2-receptor signaling through intracellular calcium mobilization and reduction of cAMP levels, triggered changes in solutes permeability and cellular junctions expression. [Microcirculation] Abstract Tamoxifen citrate, capecitabine, and epirubicin were hypothesized as interfering with cellular protein S-nitrosylation, which, in turn, may lead to endothelial dysfunctions. The results showed that all three drugs attenuated nitrosylated proteins in endothelial cells. [Clin Exp Pharmacol Physiol] Abstract Subscribe to one of our other 19 science newsletters such as Extracellular Matrix News & Cell Therapy News. | |
| |
REVIEWSThe Metabolic Engine of Endothelial Cells The authors provide an updated overview of the growing understanding of central carbon metabolic pathways in endothelial cells (ECs) and the therapeutic opportunities for targeting EC metabolism. [Nat Metab] Abstract Visit our reviews page to see a complete list of reviews in the endothelial cell research field. | |
| |
INDUSTRY NEWSFDA Approves Roche’s Rituxan (Rituximab) in Children with Two Rare Blood Vessel Disorders Roche announced that the FDA has approved Rituxan®, in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis in pediatric patients two years of age and older. [Roche] Press Release OrbusNeich® Announces Japan Approval for COMBO® Plus Coronary Stent OrbusNeich Medical K.K. of Tokyo Japan has announced that the Japan Ministry of Health, Labor, and Welfare has granted Shonin market approval for the COMBO Plus Coronary Stent. [OrbusNeich Medical K.K.] Press Release AVEO Oncology announced that it has initiated enrollment in an open-label, multi-center Phase Ib/II clinical trial evaluating FOTIVDA®, the company’s once-daily, potent and selective VEGFR tyrosine kinase inhibitor, in combination with IMFINZI®, AstraZeneca’s human monoclonal antibody directed against programmed death-ligand 1, in patients with hepatocellular carcinoma who have not received prior systemic therapy. [AVEO Oncology] Press Release | |
| |
POLICY NEWSNIH Reveals Its Formula for Tracking Foreign Influences The US National Institutes of Health (NIH) thinks it may have figured out how China’s foreign talents recruitment program is undermining its system for making awards and ensuring ethical behavior by its grantees. [ScienceInsider] Editorial The Potent Effects of Japan’s Stem-Cell Policies A five-year regulatory free-for-all in regenerative medicine has given the industry a boost. But patients might be paying the price. [Nature News] Editorial
| |
EVENTSNEW Precision Health: Molecular Basis, Technology and Digital Health Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Associate – Vascular Disease (University of Miami) Full Professorship – Translational Vascular Biomedicine (Charité – University Medicine Berlin) Postdoctoral Fellow – Ophthalmology (The University of Tennessee Health Science Center) Postdoctoral Fellow and Graduate Student – Cardiovascular Sciences (University of Calgary) Research Associate – Vascular and Skeletal Biology (Imperial College London) Postdoctoral Position – Liver Macrophage Niche (Flanders Institute for Biotechnology) Postdoctoral Position – Alzheimer’s disease (Icahn School of Medicine) Postdoctoral Position – Vascular Biology (New York University Winthrop Hospital) PhD and Postdoctoral Positions – Neurovascular Biology (Université Libre de Bruxelles) Faculty Positions – Basic and Translational Cardiovascular Sciences (New York University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Endothelial Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|